AMENDMENT

Please amend the claims as follows:

1. (Amended) A method for [inhibiting, treating, or] reducing [unwanted side effects] hypersensitivity [caused by complement activation] side effect associated with the administration of [a] an amphiphilic carrier containing pharmaceutical composition [including a drug and a solvent containing amphiphilic molecules, said method] comprising [employing] administering to a subject a complement activation inhibitor in conjunction with said composition, wherein the complement activation inhibitor is present in an amount to reduce the hypersensitivity effect.

2. (Amended) The method according to claim 1 wherein said amphiphilic molecule is polyethoxylated oil or a derivative thereof, emulsifiers or detergent molecules [thereof].

3. (Amended) The method according to claim 2 wherein the solvent is selected from the group of hydrophilic or hydrophobic solvents [that carry said amphiphilic molecules].

4. (Amended) The method according to claim 3 wherein the solvent is Cremophor or Cremophor EL.

5. (Amended) The method according to claim 1 wherein said pharmaceutical composition further comprises [drug is poorly soluble in water-based solvents and necessitates the addition of]emulsifiers [to become soluble].

6. (Amended) The method according to claim 2 wherein [said drug is selected from the group consisting essentially of :] the pharmaceutical composition includes taxol, althesin, cyclosporin, diazepham, didemnin E, echinomycin, propandid, steroids, teniposide, [and] or multivitamin products.

10. (Amended) A method for preventing a complement activation reaction in an individual resulting from the administration of a drug composition containing polyethoxilated oil, said method comprising [any one of the steps selected from the group consisting of

(i) slowly infusing said drug composition,

(ii)] administering to said individual [a high does] an effective amount of a complement activation inhibitor prior to the administration of said drug composition.